Bacteria invented it to fight viruses. In 2012 two scientists turned it into programmable DNA surgery.
CRISPR is a gene-editing tool borrowed from bacteria, which use it as an immune memory: they store viral DNA fragments between repetitive sequences and deploy the Cas9 protein to cut matching invaders. In 2012 Jennifer Doudna and Emmanuelle Charpentier showed Cas9 could be programmed to cut DNA at any chosen spot — 2020 Nobel Prize in Chemistry.
The discovery turned genetic engineering from a million-dollar craft into bench-top routine: cut the DNA, and the cell's own repair machinery can disable a gene or paste in a new sequence. Medicine, agriculture and basic research were transformed within a decade — and so was the ethical debate, when the first gene-edited babies were announced in 2018.
The story starts in 1987, when Japanese researchers noticed strange repeating sequences in E. coli DNA, and in 1993 when Francisco Mojica in Spain found the same patterns in salt-loving archaea and grasped their purpose: a diary of past infections. The acronym CRISPR — Clustered Regularly Interspaced Short Palindromic Repeats — named the repeats; the Cas proteins were the shears.
Bacteria under viral attack were keeping mugshots: snippets of attacker DNA filed between the repeats, transcribed into guide RNAs that led Cas proteins to matching viral DNA for destruction. It was adaptive immunity, a billion years before vertebrates invented antibodies — and it was programmable by nature.
Charpentier, studying the system in Streptococcus pyogenes, identified the tracrRNA component that made Cas9 work; collaborating with Doudna at Berkeley, the team showed in a landmark 2012 Science paper that Cas9 plus a fused guide RNA could be aimed at any DNA sequence in a test tube. The cut was clean, the targeting simple — a 20-letter RNA address.
In 2013 Feng Zhang's lab showed it worked in human and mouse cells, and the race was on. Doudna and Charpentier received the 2020 Nobel in Chemistry — the first science Nobel shared by two women alone. The patent fight between Berkeley and the Broad Institute ran for years and made lawyers rich; the science belonged to everyone.
CRISPR's first medical triumphs arrived fast: in December 2023 regulators approved Casgevy, a CRISPR therapy for sickle cell disease, in which patients' own blood stem cells are edited to produce fetal hemoglobin. Trials target blindness, muscular dystrophy, high cholesterol and cancers, with edited immune cells hunting tumors.
Agriculture moved in parallel: CRISPR-edited crops — disease-resistant rice and wheat, non-browning mushrooms, hornless cattle — dodge the old GMO debates in some jurisdictions because no foreign DNA is inserted. The tool is cheap enough for small labs worldwide, which is both its promise and its peril.
Editing a patient's blood cells affects one person; editing an embryo affects every descendant. In November 2018 the Chinese scientist He Jiankui announced gene-edited twin babies, edited for HIV resistance — the experiment was condemned worldwide as reckless, and he was imprisoned. The scientific consensus since: somatic editing for disease, yes; heritable editing, not yet — perhaps not ever.
CRISPR forced humanity's oldest new question: now that we can rewrite the code of life cheaply and precisely, what should we rewrite — and who decides? The scissors are in our hands; the instruction manual is still being written.
